RhumbLine Advisers’s ADC Therapeutics ADCT Stock Holding History

RhumbLine Advisers’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$390K	Buy	104,051 +13,368	+15%	+$52.7K	﹤0.01%	2758
2025 Q4	$320K	Sell	90,683 -9,791	-10%	-$39.7K	﹤0.01%	2934
2025 Q3	$402K	Sell	100,474 -2,134	-2%	-$6.73K	﹤0.01%	2837
2025 Q2	$275K	Sell	102,608 -9,021	-8%	-$19K	﹤0.01%	3047
2025 Q1	$157K	Buy	111,629 +1,592	+1%	+$2.71K	﹤0.01%	3223
2024 Q4	$219K	Buy	110,037 +14,848	+16%	+$38.9K	﹤0.01%	3147
2024 Q3	$300K	Buy	95,189 +9,212	+11%	+$29.1K	﹤0.01%	3024
2024 Q2	$272K	Buy	+85,977	New	+$342K	﹤0.01%	3059

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RhumbLine Advisers's ADCT Position: Q1 2026 in Review

RhumbLine Advisers increased its ADC Therapeutics (ADCT) stake by 15% in Q1 2026, buying an estimated $52.7K and bringing the position to 104,051 shares worth $390K. The position accounts for ﹤0.01% of the portfolio, ranked #2758.

RhumbLine Advisers first reported a position in ADCT in Q2 2024 and has held it in 8 quarters since. The position peaked at $402K in Q3 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

RhumbLine Advisers held 104,051 shares of ADC Therapeutics worth $390K as of Q1 2026.
RhumbLine Advisers bought 13,368 ADC Therapeutics shares in Q1 2026, an estimated $52.7K.
ADC Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2758 holding.
RhumbLine Advisers first reported a position in ADC Therapeutics in Q2 2024 and has held it in 8 quarters since.
RhumbLine Advisers's ADC Therapeutics position peaked at $402K in Q3 2025.
118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.